Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
J Clin Virol ; 99-100: 61-66, 2018.
Article in English | MEDLINE | ID: mdl-29331844

ABSTRACT

BACKGROUND: CMV reactivation is a major cause of severe complications in allogeneic hematopoietic stem cell transplant (HSCT) recipients. The risk of CMV reactivation depends on the serostatus (+/-) of the donor (D) and recipient (R). The reconstitution of CMV-specific T-cell responses after transplantation is crucial for the control of CMV reactivation. OBJECTIVES: The study aimed to determine the cellular immune status correlating with protection from high-level CMV viremia (>5000 copies/ml) and disease. STUDY DESIGN: We monitored CMV-specific cellular immune responses in 9 high-risk (D-/R+), 14 intermediate risk (D+/R+) and 3 low risk individuals (D+/R-), and 8 CMV negative controls (D-/R-). Interferon- γ (IFN-γ) levels as a marker for the CD8+ T-cell response were determined by the QuantiFERON-CMV-assay and compared to viral loads determined by PCR. RESULTS: Early CMV reactivation was detected in all high-risk and 13/14 intermediate risk individuals. High-level viremia was detected in 5/7 high and 7/14 intermediate risk patients. Reconstitution of the CMV-specific cellular immune response started from 3 months after transplantation and resulted in protection against CMV reactivation. Re-establishing of CMV-specific T-cell immune responses with IFN- γ levels >8.9 IU/ml is crucial for protection from high-level CMV viremia. CONCLUSIONS: Monitoring of HSCT-recipients with the QuantiFERON-CMV-assay might be of great benefit to optimize antiviral treatment.


Subject(s)
Cytomegalovirus Infections/diagnosis , Cytomegalovirus/immunology , Hematopoietic Stem Cell Transplantation/adverse effects , Immunoassay , Real-Time Polymerase Chain Reaction , Viremia/diagnosis , Virus Activation/immunology , Adult , Aged , CD8-Positive T-Lymphocytes/immunology , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/immunology , DNA, Viral/blood , Female , Germany , Humans , Immunity, Cellular , Immunoassay/standards , Interferon-gamma/blood , Male , Middle Aged , Postoperative Complications , Real-Time Polymerase Chain Reaction/standards , Tissue Donors , Transplant Recipients , Viral Load , Viremia/immunology , Young Adult
2.
J Clin Virol ; 59(1): 44-9, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24268764

ABSTRACT

BACKGROUND: The fully automated and closed LIAISON(®)XL platform was developed for reliable detection of infection markers like hepatitis B virus (HBV) surface antigen (HBsAg), hepatitis C virus (HCV) antibodies (Ab) or human immunodeficiency virus (HIV)-Ag/Ab. To date, less is known about the diagnostic performance of this system in direct comparison to the common Abbott ARCHITECT(®) platform. OBJECTIVES: We compared the diagnostic performance and usability of the DiaSorin LIAISON(®)XL with the commonly used Abbott ARCHITECT(®) system. STUDY DESIGN: The qualitative performance of the above mentioned assays was compared in about 500 sera. Quantitative tests were performed for HBsAg-positive samples from patients under therapy (n=289) and in vitro expressed mutants (n=37). For HCV-Ab, a total number of 155 selected samples from patients chronically infected with different HCV genotypes were tested. RESULTS: The concordance between both systems was 99.4% for HBsAg, 98.81% for HCV-Ab, and 99.6% for HIV-Ab/Ag. The quantitative LIAISON(®)XL murex HBsAg assay detected all mutants in comparable amounts to the HBsAg wild type and yielded highly reliable HBsAg kinetics in patients treated with antiviral drugs. Dilution experiments using the 2nd International Standard for HBsAg (WHO) showed a high accuracy of this test. HCV-Ab from patients infected with genotypes 1-3 were equally detected in both systems. Interestingly, S/CO levels of HCV-Ab from patients infected with genotype 3 seem to be relatively low using both systems. CONCLUSIONS: The LIAISON(®)XL platform proved to be an excellent system for diagnostics of HBV, HCV, and HIV with equal performance compared to the ARCHITECT(®) system.


Subject(s)
Clinical Laboratory Techniques/methods , HIV Infections/diagnosis , Hepatitis B/diagnosis , Hepatitis C/diagnosis , Automation, Laboratory/methods , HIV Antibodies/blood , HIV Antigens/blood , Hepatitis B Surface Antigens/blood , Hepatitis C Antibodies/blood , Humans , Immunoassay/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...